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possession ratio (MPR) and proportion of days covered (PDC); and persistence, days to 
the first ≥ 30-day gap on index DMT. Outcomes were compared between the GA40 and 
oral DMT cohorts. Results: The final sample was 1,779 patients (232 GA40, 1547 oral 
DMT), with mean age 45.5 years and 77.9% female. The GA40 and oral DMT cohorts 
had 0.39 versus 1.07 discontinuations/person-year, respectively, for an incidence rate 
ratio of 2.75 (p< 0.001). Kaplan-Meier analysis showed that GA40 cohort was more per-
sistent per post-index 90-day interval (p< 0.001). Mean (standard deviation) MPR and 
PDC in the GA40 cohort were 0.88 (0.18) and 0.87 (0.20), respectively, versus 0.84 (0.18) 
and 0.70 (0.30) in the oral DMT cohort (both p< 0.001). To account for differences in 
follow-up, MPR was examined in patients with maximum 210, 270, and 330 post-index 
days. Mean MPR was 0.90 (0.16) in the GA40 cohort with ≤ 210 post-index days versus 
0.86 (0.16) for oral DMT (p< 0.05); mean MPR was not significantly different between 
the cohorts with maximum 270 or 330 post-index days. Mean PDC was higher in the 
GA40 cohort in all comparisons (all p< 0.001). ConClusions: MS patients starting 
GA40 were more persistent and at least as adherent (similar on MPR and better on 
PDC) compared with those starting oral DMTs, possibly due to GA40’s safety profile 
and less-frequent dosing schedule.
PND101
CharaCteristiCs of PatieNts With relaPsiNg remittiNg multiPle 
sClerosis (rrms) takiNg iNjeCtable aND oral Disease moDifyiNg 
treatmeNts (Dmt) iN euroPe (eu)
Narayanan S1, O’Meara P2, White J3, Chan J3, Hooper R3, Baynton E3
1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos 
Healthcare, London, UK
objeCtives: DMTs to manage RRMS patients have traditionally been injectables. 
With the introduction of new oral DMTs, a better understanding of the shift in treat-
ment patterns and their impact on patient disease burden is needed. The objective 
of this study was to assess the characteristics of RRMS patients taking injectable 
and oral DMTs in the EU (5EU: UK/France/Germany/Italy/Spain). Methods: A multi-
center retrospective chart-review study of RRMS patients was conducted in the 5EU 
in 4Q2014 to collect de-identified data on diagnosis, clinical status, and treatment 
patterns. Physicians were screened for duration of practice (≥ 3yrs) and patient vol-
ume (≥ 15 MS patients/mo) and recruited from a large panel to be geographically rep-
resentative. Medical charts of the next 10 consecutive MS patients were abstracted. 
RRMS patients taking an injectable (INJ) or oral DMT were analyzed. Results: 
1394 eligible RRMS patients were included in the analysis(INJ:64%; Oral:36%). 
Patient characteristics were(INJ/Oral):age:36/38yrs, female:65%/65%, time since 
diagnosis:53/59mo, time between diagnosis and initiation of first DMT:6.7/7.2mo, 
percent on first, second, and third line DMT were(INJ/Oral):84%/30%, 14%/50%, and 
2%/16%; time on current DMT(INJ/Oral):40mo/9mo. Reasons for current DMT ini-
tiation included(INJ/Oral):efficacy against relapses(26%/26%)/efficacy for disease 
progression(12%/14%)/efficacy in early MS(17%/5%)/patient decision(10%/7%)/
oral administration (0%/28%). Patient JCV status(INJ/Oral):positive-5%/18% & not 
tested-75%/63%; number of gadolinium-enhanced & T2 lesions:0.6/1.0 & 8.8/10.1; 
percent with ≥ 1 relapse in past 12mo:43%/65%; percent with Expanded Disability 
Status Scale score of ≥ 4.5:15%/31%; percent with moderate-to-severe disability per 
physician judgment:17%/33%; percent with active or highly active disease per phy-
sician judgment:39%/57%; percent with moderate-to-severe disease per physician 
judgment:26%/52%. ConClusions: In this cohort of RRMS patients, physicians 
initiated oral DMTs predominantly as second or third-line treatment, and these 
patients may have higher disease burden compared to those receiving injectable 
DMTs. Further research is needed to evaluate the observed treatment patterns and 
treatment sequencing strategies to alleviate patient burden.
Using 6-year data and a 20-year time horizon, this model projected that the long-
term efficacy of GA in terms of disability in patients with relapsing multiple sclerosis 
was greater than anticipated, with the results also signifying cost-effectiveness of 
treatment greater than predicted at the outset of the RSS.
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objeCtives: Compare the characteristics of RRMS patients treated with DMTs in 
EU and US. Methods: A multi-center retrospective chart-review study of RRMS 
patients was conducted in US and EU in 4Q2014 to collect de-identified data on 
diagnosis, clinical status, and treatment patterns. Neurologists were screened for 
practice duration (≥ 3yrs) and patient volume (≥ 15 MS patients/mo) and recruited 
from a large panel to be geographically representative in EU (5EU:UK/Germany/
France/Italy/Spain) and US. Neurologists abstracted de-identified data from next 10 
consecutive MS patients. RRMS patients taking injectable(INJ), oral, or infusible(INF) 
DMTs were analyzed, comparing 5EU and US. Results: 1601 (INJ:56%/Oral:31%/
INF:12%) and 640 (INJ:51%/Oral:41%/INF:8%) eligible RRMS patient charts were evalu-
ated from EU and US respectively. Distribution of current DMT treatment-line was 
(5EU/US;% patients)- 1st-line:INJ-84/77, oral-30/34, INF-28/22; 2nd-line: INJ-14/19, 
oral-50/50, INF-54/46; 3rd-or-more-line:INJ-3/5, oral-20/16, INF-18/32. Duration of 
current treatment was (5EU/US;months): INJ-39.5/50.3, oral-9.5/12.4, INF-19.1/25.8. 
Top-4 reasons for current treatment-initiation was (5EU/US;% patients)- efficacy 
for relapses:INJ-26/21, oral-26/15, INF-48/15; efficacy for disease progression: INJ-
12/21, oral-14/19, INF-30/67; efficacy for early MS/CIS:INJ-17/19, oral-5/5, INF-2/7; 
patient decision:INJ-10/12, oral-7/13, INF-2/6. Among those on oral DMTs, 28%/31% 
in EU/US initiated treatment because of mode of administration. Current patient 
disease severity per physician judgment was (5EU/US;% patients)- mild:INJ-73/72, 
oral-47/53, INF-21/19; moderate: INJ-25/27, oral-47/44, INF-61/69; severe:INJ-1/0, 
oral-5/2, INF-17/13. Latest mean EDSS scores were (5EU/US): INJ-2.0/1.9, oral-2.7/2.7, 
INF-3.7/3.8. Disease relapses suffered in the last 12-month was (5EU/US;% patients)- 
none:INJ-57/58, oral-35/42, INF-42/44; one:INJ-30/27, oral-42/34, INF-27/37; two-or-
more: INJ-13/14, oral-23/24, INF-32/19. Gd-enhanced lesions in recent cranial-MRI 
were (5EU/US;mean): INJ-0.6/0.6, oral-1.0/0.9, INF-1.5/1.0. T2-lesions in recent cranial-
MRI were (5EU/US;mean): INJ-8.8/7.8, oral-10.1/8.4, INF-14.6/11.9. ConClusions: In 
this study cohort, clinical characteristics and disease burden varied by geography 
slightly, but more so, based on the different modes of DMT administration.
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objeCtives: To compare adherence to glatiramer acetate 40 mg (GA40) and oral dis-
ease-modifying therapies (DMTs; fingolimod, teriflunomide, dimethyl fumarate) using 
a US administrative claims database. Methods: Retrospective claims data analysis 
of commercial enrollees from a large US health plan who initiated GA40 or oral DMTs 
from April 2013–June 2014; DMT initiation was the index date. Patients were ≥ 18 years 
old, enrolled 6 months pre-index and ≥ 3 months post-index, and diagnosed with 
multiple sclerosis (MS). Key outcomes were: adherence, measured with medication 
